Our technology is a platform technology with a wide range of applications in wound-care. The initial indication for our lead program (VF-001) is for Venous Leg Ulcers (VLUs). The synthetic nature of this product and its suitability for deployment in the community care environment represents a considerable market opportunity for Factor Therapeutics.
We have also several programs in early development to address other serious wound applications, as well as the potential for new products in the ocular wound care space. The growth of minimally-invasive eye surgeries (i.e. glaucoma stents) means there is a major need for products to reduce corneal scarring/fibrosis. The company has significant intellectual property around new constructs that are highly suited to this application.